近畿大学ライフサイエンス研究所Kindai University Life Science Research Institute

平成26年度

巻頭言

平成26年度
ライフサイエンス研究所紀要発刊によせて
前研究所長（平成28年10月1日の人事異動により）
工藤　正俊（内科学教室消化器内科部門教授）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究に寄与するところが大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いての御協力をお願いする次第です。

平成26年度ライフサイエンス研究所紀要

内科学教室消化器内科部門（工藤　正俊　教授）

  1. Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima M, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan: Impact of histologically confirmed lymph node metastases on the patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg 259:166-170, 2014.
  2. Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, Imai H, Maekawa K, Chikugo T, Kumano M, Hyodo T, Murakami T, Chiba Y, Takeyama Y: Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 46: 22-29, 2014.
  3. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M for the Liver Cancer Study Group of Japan: Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Ann Surg 259:336-345, 2014.
  4. Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW: Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an international expert panel. Liver Int 34:174-183, 2014.
  5. Kitano M, Sakamorto H, Kudo M: Contrast-enhanced endoscopic ultrasound. Digest Endosc 26:79–85, 2014.
  6. Kudo M: Prediction of incidence risk of hepatocellular carcinoma by ultrasound elastography. Liver Cancer 3:1-5, 2014.
  7. Kitano M, Kamata K, Kudo M: Reply to Kadayifci and brugge. Endoscopy 46:358, 2014.
  8. Kawanaka M, Nishio K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G: Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy. Liver Cancer 3:41-52, 2014.
  9. Minami Y, Yagyu Y, Murakami T, Kudo M: Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma using Three-Dimensional Cone-Beam CT Angiography. Liver Cancer 3:53-61, 2014.
  10. Minami Y, Nishida N, Kudo M: Therapeutic Response Assessment of RFA for HCC: Contrast-enhanced US, CT and MRI. World J Gastroenterol20:4160-4166, 2014.
  11. Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M: Relevance of the core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a± ribavirin for chronic hepatitis C of genotype 1b: A multicenter randomized trial, ReGIT-J study. J Gastroenterol 49:492-501, 2014.
  12. Hatanaka K, Minami Y, Kudo M, Inoue T, Chung H, Haji S: The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US. J Clin Ultrasound 42:1-8, 2014.
  13. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, FuruseJ, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 68:609-617, 2014.
  14. Kudo M, Arizumi T, Ueshima K: ART score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 59:2424-2425, 2014.
  15. Kudo M: Recent advances in Bioinformatics reveal the molecular heterogeneity of hepatocellular carcinoma. Liver Cancer 3:68-70, 2014.
  16. Togashi Y, Sakamoto H, Hayashi H, Terashima M, Velasco MA, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Kudo M, Nishio K: Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Mol Cancer 13:126, 2014.
  17. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen CL, Dorval E, Radosavljevic MPR, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. J Am Med Assoc (JAMA) 312:57-67, 2014.
  18. Ikeda N, Imanishi H, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Siato M, Iijima H, Iimuro Y, Fujimoto J, Yamamoto S, Hirota S, Kudo M, Arii S, Nishiguchi S: Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count. Hepato Res 44:829-836, 2014.
  19. Kim SR, Kondo F, Otono Y, Imoto S, Ando K, Hirakawa M, Fukuda K, Sakaki M, Kim SK, Komaki T, Tsuchida S, Kobayashi S, Matsuoka T, Kudo M: Serum amyloid A and C-reactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosis. Hepatol Res 44:584-590, 2014.
  20. Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M, for the Liver Cancer Study Group of Japan: Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1,160 cases from a nationwide survey. Ann Surg 259:532-542, 2014.
  21. Kitano M, Kamata K, Kudo M: Endoscopic ultrasonography-guided gallbladder drainage procedures: is the glass half-full or half-empty? Digest Endosc 26:636-637, 2014.
  22. Ogawa K, Fukunaga K, Takeuchi T, Kawagishi N, Ubara Y, Kudo M, Ohkohchi N: Current treatment status of polycystic liver disease in Japan. Hepatol Res 44:1110-1118, 2014.
  23. Kudo M: Biomarkers and personalized sorafenib therapy. Liver Cancer 3:399-404, 2014.
  24. Nishida N, Kudo M: Alteration of epigenetic profile in human hepatocellular carcinoma and its clinical implications. Liver Cancer 3:417-427, 2014.
  25. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K, on behalf of the Liver Cancer Study Group of Japan: JSH cnsensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458-468, 2014.
  26. Kudo M: Emerging strategies for the management of hepatocellular carcinoma. Digest Dis 32:655-657, 2014.
  27. Nishida N, Nishimura T, Nakai T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Kudo M: Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma. Digest Dis 32:658-663, 2014.
  28. Kono M, Inoue T, Kudo M, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Ueshima K, Nishida N, Murakami T: Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: Results and risk factors for local recurrence. Digest Dis 32:670-677, 2014.
  29. Minami Y, Kudo M: Ultrasound fusion imaging of hepatocellular carcinoma: a review of current evidence. Diegst Dis 32:690-695, 2014.
  30. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M: Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Digest Dis 32:705-710, 2014.
  31. Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T, for the Liver Cancer Study Group of Japan: Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score, and BCLC system) in 4,649 cases from a Japanese nationwide survey. Digest Dis 32:717-724, 2014.
  32. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M: Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma. Digest Dis 32:733-739, 2014.
  33. Nishida N, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Kudo M: Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking. Digest Dis 32:740-746, 2014.
  34. Nishida N, Kudo M: Clinical features of vascular disorders associated with chronic hepatitis virus infection. Digest Dis 32:786-790, 2014.
  35. Wu T, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ: Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study. Digest Dis 32:791-799, 2014.
  36. Kudo : Breakthroughs in the management of hepatocellular carcinoma: celebrationg 50 years of the Liver Cancer Study Group of Japan. Oncology 87:1-6, 2014.
  37. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, on behalf of the Liver Cancer Study Group of Japan: Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology 87:7-21, 2014.
  38. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, on behalf of the Liver Cancer Study Group of Japan: Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology 87:22-31, 2014.
  39. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M: Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma　proposed by LCSGJ. Oncology 87:32-36, 2014.
  40. Kondo F, Fukusato T, Kudo M: Pathological diagnosis of benign hepatocellular nodular lesions based on the new world health organization classification. Oncology 87:37-49, 2014.
  41. Ogawa C, Minami Y, Morioka Y, Noda A, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki N, Shibatouge M, Kudo M: Virtual sonography for novice sonographer: usefulness of synapse vincent○R with pre-check imaging of tumor location. Oncology 87:50-54, 2014.
  42. Minami T, Minami Y, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Inoue T, Hagiwara S, Ueshima K, Nishida N, Kudo M: Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging. Oncology 87:55-62, 2014.
  43. Yada N, Kudo M, Kawada N, Sato S, Osaki Y, Ishikawa A, Miyoshi H, Sakamoto M, Kage M, Nakashima O, Tonomura A: Noninvasive diagnosis of liver fibrosis: utility of data mining of both ultrasound elastography and serological findings to construct a decision tree. Oncology 87:63-72, 2014.
  44. Ikeda K, Osaki Y, Nakanishi H, Nasu A, Kawamura Y, Jyoko K, Sano T, Sunakozaka H, Uchino Y, Minami Y, Saito Y, Nagai K, Inokuchi R, Kokubu S, Kudo M: Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology 87:73-77, 2014.
  45. Yamakado K, Kudo M: Treatment strategies of Intermediate-stage hepatocellular carcinomas in Japan (Barcelona clinic liver cancer stage B). Oncology 87:78-81, 2014.
  46. Nouso K, Kokudo N, Tanaka M, Kuromatsu R, Nishikawa H, Toyoda H, Oishi N, Kuwaki K, Kusanaga M, Sakaguchi T, Morise Z, Kitai S, Kudo M: Treatment of hepatocellular carcinoma with Child-Pugh C cirrhosis. Oncology 87:99-103, 2014.
  47. Tanaka K, Shimada M, Kudo M: Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th annual meeting of the Liver Cancer Study Group of Japan. Oncology 87:104-109, 2014.
  48. Takita M, Hagiwara S, Kudo M, Kono M, Chishina H, Arizumi T, Kitai S, Yada N, Inoue T, Minami Y, Ueshima K: Efficacy and safety of Telaprevir-based antiviral treatment for elderly patients with hepatitis C virus. Oncology 87:110-117, 2014.
  49. Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Inoue T, Hagiwara S, Ueshima K, Nishida N, Kudo M: Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C. Oncology 87:118-123, 2014.
  50. Kudo M, Han G, Finn RS, Poon RTP, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Cruz CD, poulart V, Wang JH: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase Ⅲ trial. Hepatology 60:1697-1707, 2014.
  51. Ashida R, Yasukawa S, Yanagisawa A, Kamata K, Kudo M, Ogura T, Higuchi K, Fukutake N, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Kitano M: Prospective Multicenter Randomized Controlled Trial of Histological Diagnostic Yield Comparing 25G EUS-FNA Needles With and Without a Core Trap in Patients With Solid Pancreatic Masses. Gastrointest Endosc 79:AB111, 2014.
  52. Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Kudo M, Jang JW, Sharma R: Dynamic changes of the inflammation based index (IBI) predict mortality following chemoembolization for hepatocellular carcinoma: a prospective study. Aliment Pharm Ther 40:1270-1281, 2014.
  53. Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J, Kudo M: Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer. Cancer Res 74:6119-6128, 2014.
  54. Watanabe T, Asano N, Meng G, Yamashita K, Arai Y, Sakurai T, Kudo M, Fuss IJ, Kitani A, Shimosegawa T, Chiba T, Strober W: NOD2 Down-regulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6. Mucosal Immunol 7:1312-1325, 2014.
  55. Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M: Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol 49:1578-1587, 2014.
  56. Taki H, Taki K, Yamakawa M, Shiina T, Kudo M, Sato T: Stabilization technique for real-time high-resolution vascular ultrasound using frequency domain interferometry. Conf Proc IEEE Eng Med Biol Soc 5085-5088, 2014.
  57. Adachi T, Sakurai T, Kashida H, Mine H, Hagiwara S, Matsui S, Yoshida K, Nishida N, Watanabe T, Itoh K, Fujita J, Kudo M: Involvement of heat shock protein A4/Apg-2 in refractory inflammatory bowel disease. Inflamm Bowel Dis 21:31-39, 2015.
  58. Kudo M: Malignant transformation of hepatocellular adenoma: How frequently does it happen? Liver Cancer 1:1-5, 2015.
  59. Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K: Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett 356:819-827, 2015.
  60. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, Nowiem SE: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33:172-179, 2015.
  61. Okumura N, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Kawasaki M, Tomita T, Umehara Y, Taniike S, Kono M, Kudo M: Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infection. Gastroenterol Rep 3:69-74, 2015.
  62. Nishida N, Kudo M: A bridge between multi-omics data and the management of hepatocellular carcinoma. Ann Transl Med 3:1, 2015.
  63. Kudo M: Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 4:39-50, 2015.
  64. Kudo M: Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe. Liver Cancer 4:85-95, 2015.
  65. Kitano M, Kamata K, Imai H, Miyata T, Yasukawa S, Yanagisawa A, Kudo M: Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliaty diseases. Digest Endosc 27:60-67, 2015.
  66. Sakamoto H, Kitano M, Kudo M: EUS-guided broad plexus neurolysis technique and its indications. Diagnostic Imaging Asia-Pacific, 2015 (in press).
  67. Lencioni R, Kudo M, Venook A, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Marrero JA: Second IA of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) non-interventional study. Liver Int, 2015 (in press).
  68. Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M: Multicenter cooperative case survey of hepatitis B Virus reactivation by chemotherapeutic agents. Hepatol Res. 2015 Jan 27.
  69. Nishida N, Kudo M: Clinical manifestation and treatment of vasculitis related to hepatitis virus infection. Clinical and Developmental Immunology, 2015 (in press).
  70. Nishikawa H, Enomoto H, Saito M, Aizawa N, Tsuda Y, Higuchi K, Okazaki K, Seki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M, Osaki Y, Nishiguchi S: Treatment response and tolerability in elderly patients with chronic hepatitis C: subgroup analysis in ReGIT-J study. Acta Gastro-Ent Belg, 2015 (in press).
  71. Arai Y, Yamashita K, Mizugishi K, Kadowaki N, Tadaori-Kondo A, Kuriyama K, Shiokawa M, Kodama Y, Sakurai T, Kudo M, Okazaki K, Chiba T, Watanabe T: Sensing of neutrophil extracellular traps by plasmacytoid dendritic cells mediates lgG4-related disease. Gastroenterology, 2015 (in press).
  72. Ye SL, Lencioni R, Marrero JA, Venook AP, Nakajima K, Kudo M: Treatment patterns in >3000 sorafenib-treated patients: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib). Chinese Soceity of Clinical Oncology (CSCO), 2015 (in press).
  73. Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan: Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Clin Gastroenterol H, 2015 (in press).
  74. Wu T, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ: Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study. Dig Dis. 2014;32(6):791-9.
  75. Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JFH, Ladron de Guevara L, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R: Observational registry study of sorafenib use in clinical practice across Child-Pugh subgroups: final analysis of GIDEON. J Hepatol, 2015 (in press).
  76. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res, 2015 Jan;45(2).
  77. Kudo M: Challenges and future prospects of clinical research on hepatocellular carcinoma. Liver Cancer, 2015 (in press).
  78. Kudo M: General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the extensive achievements of the Liver Cancer Study Group of Japan. Dig Dis. 2015 Oct;33(6):765-70.
  79. Minami Y, Kudo M: Imaging response assessment of HCC with nonsurgical therapy including RFA and TACE: Contrast-enhanced US, CT and MRI. Liver Cancer, 2015 (in press).
  80. Kono M, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Okumura N, Kawasaki M, Tomita T, Umehara Y, Taniike S, Hatabe S, Funai S, Ono Y, Ochiai K, Maekura S, Kudo M: Primary leiomyosarcoma of the colon. Clin J Gastroenterol. 2015 Aug;8(4):217-22.
  81. Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R: TACE treatment in sorafenib-treated unresectable hepatocellular carcinoma patients in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib). Radiology, 2015 (in press).
  82. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kokudo N, and for the Liver Cancer Study Group of Japan: Impact of resection and ablation for hypovascular hepatocellular carcinoma with propensity score weighting based on a Japanese nationwide survey. J Hepatol, 2015 (in press).
  83. Sakurai T, Yada N, Watanabe T, Arizumi T, Hagiwara S, Ueshima K, Nishida N, Fujita J, Kudo M: Cold-inducible RNA-binding protein (Cirp) promotes the development of liver cancer. Cancer Sci. 2015 Apr;106(4):352-8.
  84. Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M and the investigators'study group: Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. J Hepatol. 2015 Oct;63(4):896-904.
  85. Sakurai T, Kashida H, Hagiwara S, Nishida N, Watanabe T, Fujita J, Kudo M: Heat shock protein A4 controls cell migration and gastric ulcer healing. Dig Dis Sci. 2015 Apr;60(4):850-7.
  86. Matsui S, Kudo M, Kitano M, Asakuma Y: Evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS. Hepato-Gastroenterol, 2015 (in press).
  87. Kudo M: Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy. Hepatol Int. 2015 Apr;9(2):155-6.
  88. Kang YK, Yau T, Park JW, Boucher E, Lim HY, Lee TY, Obi S, Chan SL, Qin SK, Kim RD, Tang J, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M: Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015 Sep 18. pii: mdv388. [Epub ahead of print]
  89. Hagiwara S, Nishida N, Park AM, Sakurai T, Kawada A, Kudo M: Impaired expression of multidrug resistance-associated protein 2 and liver damage in erythropoietic protoporphyria. Hepatology, 2015 (in press).

病理学教室（伊藤　彰彦　教授）

  1. Takashi Kato, Shinya Mizuno and Akihiko Ito: A Decrease in Glomerular Endothelial Cells and Endothelial-mesenchymal Transitionduring Glomerulosclerosis in the Tensin2-deficient Mice (ICGN strain). Acta Histochem. Cytochem. 47 (6): 265–271, 2014
  2. Togashi Y, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Ito A, Kudo M, Nishio K.: Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Mol Cancer. 2014 May 27;13:126.
  3. 伊藤彰彦　大学院医学研究シリーズ　ヒトに由来する研究試料の取り扱い～病理学の立場から～　近畿大学誌(Med Kinki Univ)　第39巻3,4号　155～161 2014
  4. Minami A. Sakurai, Yuki Ozaki1, Daisuke Okuzaki, Yoko Naito, Towa Sasakura, Ayumi Okamoto, Hiroe Tabara, Takao Inoue, Man Hagiyama, Akihiko Ito, Norikazu Yabuta, Hiroshi Nojima: Gefitinib and Luteolin Cause Growth Arrest of Human Prostate Cancer PC-3 Cells via Inhibition of Cyclin GAssociated Kinase and Induction of miR-630. PLoS One. 2014 Jun 27;9(6):e100124.
  5. Takao Inoue., Man Hagiyama., Azusa Yoneshige, Takashi Kato, Eisuke Enoki, Osamu Maenishi,Takaaki Chikugo, Masatomo Kimura, Takao Satou, Akihiko Ito:
    Increased Ectodomain Shedding of Cell Adhesion Molecule 1 from Pancreatic Islets in Type 2 Diabetic Pancreata: Correlation with Hemoglobin A1c Levels. PLoS One. 2014 Jun 25;9(6):e100988.
  6. Mimae T, Hagiyama M, Inoue T, Yoneshige A, Kato T, Okada M, Murakami Y, Ito A.: Increased ectodomain shedding of lung epithelial cell adhesion molecule 1 as a cause of increased alveolar cell apoptosis in emphysema. Thorax. 2014 Mar;69(3):223-31.

免疫学教室（宮澤　正顯　教授）

  1. Kato M, Tsuji-Kawahara S, Kawasaki Y, Kinoshita S, Chikaishi T, Takamura S, Fujisawa M, Kawada A, Miyazawa M. Class switch recombination and somatic hypermutation of virus-neutralizing antibodies are not essential for control of friend retrovirus infection. J Virol. 2015 Jan 15;89(2):1468-73.
  2. Hakata Y, Miyazawa M, Landau NR. Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest. Virol J. 2014 Jun 9;11:108.
  3. Tsuji-Kawahara S, Takamura S, Miyazawa M. Reply to "CD8＋ T Cells Are Essential for Controlling Acute Friend Virus Infection in C57BL/6 Mice".
    J Virol. 2014 May;88(9):5202-3.
  4. Hakata Y, Tsuchiya S, Michiue H, Ohtsuki T, Matsui H, Miyazawa M, Kitamatsu M. A novel leucine zipper motif-based hybrid peptide delivers a functional peptide cargo inside cells. Chem Commun (Camb). 2015 Jan 7;51(2):413-6.

細菌学教室（義江　修　教授）

  1. Takeshi Okuda, Hidetoshi Hayashi, Mitsugu Fujita, Hiromasa Yoshioka, Takayuki Tasaki, Kazuhiko Nakagawa, Amami Kato: Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis. Int Canc Conf J (2014) 3:211-214
  2. Takeshi Okuda,Juli Yamashita , Mitsugu Fujita ,Hiromasa Yoshioka , Takayuki Tasaki,Amami Kato: The chicken egg and skull model of endoscopic endonasal transsphenoidal surgery improves trainee drilling skills. Acta Neurochir (2014) 156:1403–1407
  3. Nakata S, Tanaka H, Ito Y, Hara M, Fujita M, Kondo E, Kanemitsu Y, Yatabe Y, Nakanishi H. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity. Int J Oncol. 2014 Oct;45(4):1583-93.
  4. Hiromasa Yoshioka, Takeshi Okuda, Mitsugu Fujita, Takao Inoue, Takayuki Tasaki, Shuichi Izumoto, Amami Kato: Inhibition of ABCG2 enhances chemo-sensitivity of murrine glioma stem cell-like cell to temozolomide and reduces spheroid-forming capability. Acta Med Kinki Univ Vol.39,No.2 105-113,2014
  5. 下村嘉一，松本長太，福田昌彦，奥山幸子，園吉一樹，杉岡孝二，板橋幹城，橋本茂樹，青松圭一，七部史，野本裕貴，渡遺敬三，河本庄平，児玉彩，坂本万寿 夫，日下俊次，檎垣史郎，小池英子，立花都子，辻岡大志，三島弘，阿部考助，萱澤朋泰，萱澤真梨子，藤田貢，義江修． ヘルペスと闘った 37 年． 日本眼科学会雑誌 119巻 3号 (平成 27 年 3 月)

ゲノム生物学教室（西尾　和人　教授）

  1. Koike H, Nozawa M, De Velasco MA, Kura Y, Ando N, Fukushima E, Yamamoto Y, Hatanaka Y, Yoshikawa K, Nishio K, Uemura H. Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model. Asian Pac J Cancer Prev, 16(5): 1827-31, 2015.
  2. Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K. Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. Anticancer Res, 35(3): 1683-9, 2015.
  3. Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K. Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. Lung Cancer, 88(1): 16-23, 2015.
  4. Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett, 356(2 Pt B): 819-27, 2015.
  5. Yamaguchi T, Kurita T, Nishio K, Tsukada J, Hachisuga T, Morimoto Y, Iwai Y, Izumi H. Expression of BAF57 in ovarian cancer cells and drug sensitivity. Cancer Sci, E-pub ahead of print, 2015.
  6. Kogita A, Yoshioka Y, Sakai K, Togashi Y, Sogabe S, Nakai T, Okuno K, Nishio K.　Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.　Biochem Biophys Res Commun, 458(1): 52-6, 2015.
  7. Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Nishio K, et al. Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. Springerplus, 4: 7, 2015.
  8. Banno, E, Togashi Y, Kobayashi Y, Hayashi H, Mitsudomi T, Nishio K. Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion. Anticancer Res, 35(4): 2005-8, 2015.
  9. Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. Int J Oncol, 46(3): 1025-30, 2015.
  10. Yamaguchi Y, Yamaue H, Okusaka T, Okuno K, Suzuki H, Fujioka T, Otsu A, Ohashi Y, Shimazawa R, Nishio K, Furuse J, Minami H, Tsunoda T, Hayashi Y, Nakamura Y. Guidance for peptide vaccines for the treatment of cancer. Cancer Sci, 105(7): 924-31, 2014.
  11. Kimura M, Makio K, Hara K, Hiruma W, Fujita Y, Takata T, Nishio K, Ono N. A Supramolecular Substance, [2] Rotaxane, Induces Apoptosis in Human Molt-3 Acute Lymphoblastic Leukemia Cells. Drug Res, E-pub ahead of print, 2014.
  12. Shiotani A, Murao T, Fujita Y, Fujimura Y, Sakakibara T, Nishio K, Haruma K. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. Journal of Gastroenterology and Hepatology, 4: 47-52, 2014.
  13. Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K, Nakagawa K. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget, 5(23): 11847-56, 2014.
  14. Sogabe S, Togashi Y, Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, Develasco MA, Sakai K, Fujita Y, Tomida S, Yasuda T, Takeyama Y, Okuno K, Nishio K. MEK inhibitor for gastric cancer with MEK1 gene mutations. Mol Cancer Ther, 13(12): 3098-106, 2014.
  15. Sakai K, Kazama S, Nagai Y, Muruno K, Tanaka T, Ishihara S, Sunami E, Tomida S, Nishio K, Watanabe T. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget, 5(20): 9641-9, 2015.1
  16. Tanioka M, Sakai K, Sudo T, Sakuma T, Kajimoto K, Hirokage K, Takao S, Negoro S, Minami H, Nakagawa K, Nishio K. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer. Breast Cancer Research and Treatment, 147(3): 513-25, 2015.1
  17. Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K. Inhibition of β-catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small cell lung cancer with a T790M mutation. J Thorac Oncol, 10(1): 93-101, 2015.
  18. Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer, E-pub ahead of print, 2014.
  19. Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. Int J Oncol, 45(4): 1430-6, 2014.1.
  20. Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K. Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. Springerplus, 3: 417, 2014.
  21. Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K, Nishio K. Targeting MET Amplification as a New Oncogenic Driver. Cancers(Basel), 6(3): 1540-52, 2014.
  22. Terashima M, Fujita Y, Togashi Y, Sakai K, Velasco MA, Tomida S, Nishio K. KIAA1199 interacts with glycogen phosphorylase kinase b-subunit (PHKB) to promote glycogen breakdown and cancer cell survival. Oncotarget, 5(16): 7040-50, 2014.
  23. Kim H, Terazono H, Nakamura Y, Sakai K, Hattori A, Odaka M, Girault MA, Arao T, Nishio K, Miyagi K, Yasuda K. Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells. PLOS ONE, 9(8): e104372, 2014.
  24. Togashi Y, Hayashi H, Nakagawa K, Nishio K. Clinical utility of erlotinib for the treatment of non-small cell lung cancer in Japanese patients: current evidence. Drug Design, Development and Therapy, 8: 1037-46, 2014.7
  25. Sakai K, Takeda M, Okamoto I, Nagakawa K, Nishio K. Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. Oncology Letter, 9(1): 405-410, 2015.
  26. Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer, 14: 530, 2014.7
  27. Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K, Takahashi K. Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer. PLOS ONE, 9(7): e102436, 2014.
  28. De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H. Androgen Deprivation Induces Phenotypic Plasticity and Promotes Resistance to Molecular Targeted Therapy in a PTEN-deficient Mouse Model of Prostate Cancer. Carcinogenesis, 35(9): 2142-53, 2014.
  29. Togashi Y, Arao T, Kato H, Matsumoto K, Terashima M, Hayashi H, de Velasco MA, Fujita Y, Kimura H, Yasuda T, Shiozaki H, Nishio K. Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget, 5(10): 2962-73, 2014.
  30. Hayashi H, Arao T, Matsumoto K, Kimura H, Togashi Y, Hirashima Y, Horita Y, Iwasa S, Okita NT, Honma Y, Takashima A, Kato K, Hamaguchi T, Shimada Y, Nakagawa K, Nishio K, Yamada Y. Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget, 5(9): 2588-95, 2014.
  31. Togashi Y, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Ito A, Kudo M, Nishio K. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Molecular Cancer, 13: 126, 2014.
  32. Fujita Y, Koinuma S, Develasco MA, Bolz J, Togashi Y, Terashima M, Hayashi H, Matsuo T, Nishio K. Melanoma transition is frequently accompanied by a loss of cytoglobin expression in melanocytes: a novel expression site of cytoglobin.
    PLOS ONE, 9(4): e94772, 2014.
  33. Nagasawa I, Kaneko A, Suzuki T, Nishio K, Kinoshita K, Shiro M, Koyama K. Potential Anti-angiogenesis Effects of p-Terphenyl Compounds from Polyozellus multiplex. J Nat Prod, 77(4): 963-8, 2014.
  34. Kimura H, Ohira T, Uchida O, Matsubayashi J, Shimizu S, Nagao T, Ikeda N, Nishio K. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer, 83(3): 329-33, 2014.

archive

近畿大学
近畿大学医学部

Copyright (C) Kindai University Life Science Research Institute All rights reserved.